The degradation profile of novel, bioresorbable PCL-TCP scaffolds:: An in vitro and in vivo study
The degradation profile of novel, bioresorbable PCL-TCP scaffolds:: An in vitro and in vivo study
复制标题
DOI：
10.1002/jbm.a.31454
复制
发表时间：
2008-01-01
影响因子：
4.9
通讯作者：
Teoh, S. H.
中科院分区：
文献类型：
--
作者：
Yeo, A.;Rai, B.;Teoh, S. H.
支架材料的降解研究在骨组织工程中具有重要意义。以前，基于新型聚己内酯-20%磷酸三钙(PCL-TCP)的支架被开发并被证明是有用的骨再生材料。在本研究中，PCL-TCP支架在标准培养基中浸泡24周后进行了体外降解分析。将支架植入大鼠腹部相同时间进行体内降解实验。结果表明，PCL-TCP支架在体内的降解率高于体外。24周时，体内支架的平均孔隙率由体外的2.65%增加到29.2%。凝胶渗透色谱(GPC)分析显示，体外培养24周后，M-n和M-w值分别下降了29%和20%。然而，在活体内，M-n和M-w值显著下降(分别为79.6%和88.7%)。然而，即使在24周时，力学性能也相对相似，与松质骨的力学性能非常接近。结果表明，该支架可用于牙槽骨重建，PCL-TCP支架可在5~6个月的时间内降解，具有良好的力学性能。(C)2007年威利期刊公司《生物医学杂志》84A：208-218,2008。
Degradation studies of scaffolds are important in bone tissue engineering. Previously, novel poly(epsilon-caprolactone) - 20% tricalcium phosphate (PCL - TCP) based scaffolds were developed and proven useful for bone regeneration. In this study in vitro degradation analyses were carried out with the PCL - TCP scaffolds immersed in standard culture medium for 24 weeks. In vivo degradation was performed with the scaffolds implanted in the abdomen of rats for the same period of time. Results demonstrated greater degradation of PCL - TCP scaffolds hi vivo than in vitro. At 24 weeks, the increase of average porosity of the scaffolds in vivo was 29.2% compared to 2.65% in vitro. Gel permeation chromatography (GPC) analysis revealed a decrease of 29% and 20% respectively in the M-n and M-w values after 24 weeks in vitro. However, a significant decrease in M-n and M-w values (79.6% and 88.7% respectively) were recorded in vivo. The mechanical properties however, were relatively similar and closely match those of cancellous bone even at 24 weeks. The results showed that the scaffold can be used for dentoalveolar reconstruction and PCL - TCP scaffolds have shown to possess the potential to degrade within the desired time period of 5 - 6 months and favorable mechanical properties. (c) 2007 Wiley Periodicals, Inc. J Biomed Mater Res 84A: 208-218,2008.